Literature DB >> 17944733

Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis.

N Snowberger1, S Chinnakotla, R M Lepe, J Peattie, R Goldstein, G B Klintmalm, G L Davis.   

Abstract

BACKGROUND: Serum alpha fetoprotein (AFP), ultrasound, computerized tomography scanning, and magnetic resonance imaging are commonly used to screen for hepatocellular carcinoma (HCC) in patients with cirrhosis. AIM: To assess the accuracy of screening in advanced cirrhosis.
METHODS: The study group consisted of 239 patients with proven HCC in the explanted liver at the time of liver transplant. AFP and imaging were done at referral and serially until transplant.
RESULTS: Hepatocellular carcinoma was detected before liver transplant in 78% and discovered incidentally in 22%. The cause of cirrhosis was hepatitis C (HCV) (55%), hepatitis B (HBV) (17%), alcohol (9%), and other/unknown (19%). Although AFP was elevated 62%, the median level was 15 ng/mL. Only 26%, 15% and 13% were more than 100, 400 and 1000 ng/mL, respectively. By comparison, AFP was elevated in 20% without HCC, but exceeded 100 ng/mL in only 3%. The overall accuracy of AFP was poor regardless of the cutoff. Magnetic resonance imaging was more accurate than computerized tomography or ultrasound in detecting tumour, particularly when performed within 3 months of transplant.
CONCLUSIONS: Magnetic resonance imaging is most sensitive for imaging HCC and best reflects actual tumour size. AFP is insensitive and adds little to screening strategies, but has prognostic value when extremely elevated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17944733     DOI: 10.1111/j.1365-2036.2007.03498.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  29 in total

1.  Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma.

Authors:  Peng Li; Shan-Shan Wang; Hui Liu; Ning Li; Michael A McNutt; Gang Li; Hui-Guo Ding
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

Review 2.  Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

3.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

4.  Superparamagnetic Iron Oxide-enhanced Magnetic Resonance Imaging of Spontaneous Hepatic Neoplasia in a Cynomolgus Macaque (Macaca fascicularis).

Authors:  Yasuyo Ito Fujishiro; Hiroshi Koie; Shunya Nakayama; Hiroaki Shibata; Sachi Okabayashi; Yuko Katakai; Kiichi Kanayama; Yasuhiro Yasutomi; Naohide Ageyama
Journal:  Comp Med       Date:  2018-05-29       Impact factor: 0.982

5.  GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer.

Authors:  De-Yong Gao; Yun Ling; Xiao-Li Lou; Ying-Ying Wang; Liang-Ming Liu
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

6.  The healthcare burden imposed by liver disease in aging Baby Boomers.

Authors:  Gary L Davis; William L Roberts
Journal:  Curr Gastroenterol Rep       Date:  2010-02

7.  Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

Authors:  Egesta Lopci; Guido Torzilli; Dario Poretti; Lauro J Souza de Neto; Matteo Donadon; Lorenza Rimassa; Ezio Lanza; Juliano Guerra Sabongi; Roberto Ceriani; Nicola Personeni; Angela Palmisano; Vittorio Pedicini; Tiziana Comito; Marta Scorsetti; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-12       Impact factor: 9.236

Review 8.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

9.  Hepatocellular carcinoma: management of an increasingly common problem.

Authors:  Gary L Davis; Jane Dempster; James D Meler; Douglas W Orr; Mark W Walberg; Brian Brown; Brian D Berger; John K O'Connor; Robert M Goldstein
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-07

10.  Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.

Authors:  Robert G Gish; Richard S Finn; Jorge A Marrero
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.